Clinical Trials - ACHV

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06435221Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette SmokersACTIVE_NOT_RECRUITINGPHASE32024-05-282025-12-312025-12-31
NCT05981768Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult SmokersCOMPLETEDPHASE12023-08-082023-09-212023-09-21
NCT05631938Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline DoseCOMPLETEDPHASE12023-01-102023-09-042023-09-04
NCT05566288Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy SmokersCOMPLETEDPHASE12022-10-172022-12-232022-12-23
NCT05431387A Study of Cytisinicline for Vaping Cessation in Adult SmokersCOMPLETEDPHASE22022-07-132023-02-282023-02-28
NCT05206370A Second Study of Cytisinicline for Smoking Cessation in Adult SmokersCOMPLETEDPHASE32022-01-202023-03-212023-03-21
NCT04576949A Study of Cytisinicline for Smoking Cessation in Adult SmokersCOMPLETEDPHASE32020-10-132021-12-232021-12-23
NCT03848208A Single Dose-escalation Study of Cytisine in Adult SmokersCOMPLETEDPHASE12019-02-282019-09-122019-09-12
NCT03709823Trial of Cytisine in Adult SmokersCOMPLETEDPHASE22018-11-132019-04-232019-04-23
NCT03509948A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New FormulationCOMPLETEDPHASE12018-04-272018-06-122018-06-10
NCT03303911A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy SmokersTERMINATEDPHASE1, PHASE22017-10-062018-10-052018-10-05
NCT03268343A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of CytisineCOMPLETEDPHASE12017-08-082017-09-012017-08-26
NCT01874561Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac RepolarizationCOMPLETEDPHASE12013-052014-012013-12
NCT01630733A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerUNKNOWNPHASE32012-092017-072017-07
NCT01578655Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate CancerCOMPLETEDPHASE32012-082016-072016-07
NCT01497470A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment RegimenCOMPLETEDPHASE12012-042013-102013-07
NCT01454089A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder CancerCOMPLETEDPHASE22011-102014-112014-11
NCT01188187Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate CancerCOMPLETEDPHASE32010-112014-062014-02
NCT01083615A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TERMINATEDPHASE32010-032013-032013-03
NCT00487786Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder CancerCOMPLETEDPHASE12007-062011-102011-06
NCT00385177Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid TumorsCOMPLETEDPHASE12006-092009-052008-12
NCT00327340Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCCOMPLETEDPHASE22006-072010-102010-10
NCT00251095Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast CancerTERMINATEDPHASE32005-092007-092007-09
NCT00138658A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)COMPLETEDPHASE1, PHASE22004-112010-032010-03
NCT00096668Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast CancerCOMPLETEDPHASE22004-102007-092007-09
NCT00077688TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the UrotheliumCOMPLETEDPHASE22003-112007-09
NCT00034164Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung CancerCOMPLETEDPHASE22002-042007-092007-09
NCT00034177Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the UrotheliumCOMPLETEDPHASE22002-042007-092007-09
NCT00034190Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal AdenocarcinomaCOMPLETEDPHASE22002-032007-092007-09
NCT00034151Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian CancerCOMPLETEDPHASE22002-032007-092007-09